CTRI/2019/03/018264进行中（未招募）3 期
A,Prospective, Randomized, Double Blind,Parallel Design,Placebo Controlled Study to Evaluate The Safety And Efficacy Of AKBA ULTRAâ?¢ In the Management Of Clinical Symptoms Of Osteoarthritis. - AKBA/APPL/K18CT001
Ambe Phytoextracts Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Patients with osteoarthritis of the knee joints X ray screened, with no other known rheumatological condition and who report the following clinical features based on the ACR classification for knee OA.
- •-knee pain on most days of the previous month, -morning stiffness of less than thirty minutes duration
- •-stiffness in resting the joint.
- •2.Patients who have been on stable medication conventional or complementary, including nutritional medicine for the past three months, but are still getting symptoms incomplete responders.
- •3.Patients with visual analog scale VAS score that assessed pain during the most painful knee movement had to be more than forty.
- •4.Patients able to walk and give both verbal and written information regarding the study.
- •5.Willing to give written informed consent.
- •6.Patients willing to and able to comply with all trial requirements.
- •7.Patients who have not participated in a similar investigation in the past four weeks.
- •8.Female patients with negative UPT.
- •9.Female patients with child bearing potential must be willing to agree to use effective contraceptive methods while on treatment and for three months after the completion of study.
- •10. Male and female Volunteers, with age between 40to70 years
- •11.Patients with functional index more than seven points.
排除标准
- •1. Patients with clinical evidence or known history of severe cardiac, pulmonary, gastrointestinal, renal, hepatic or neurological disorders
- •2. History of allergy to aspirin or NSAIDs.
- •3. Patients who have undergone total knee replacement in the contralateral knee within 6 months prior to the screening visit.
- •4. Patients who have received an intra articular corticosteroid injection in a lower joint during the three months prior to the baseline visit.
- •5. Patients with isolated lateral compartment disease defined by joint space loss in the lateral compartment only.
- •6. Patients who have received chondrocyte transplants in any lower extremity joint.
- •7. Patients with comorbid conditions that restrict knee function.
- •8. Patients taking treatment with corticosteroids within last 3 months.
- •9. Patient with infectious arthritis or gout or underlying inflammatory arthropathy or hyperuricemia
- •10. Patients with recent injury in the area affected by OA of the knee.
- •11. Patients with abnormal liver or kidney function tests, major abnormal finding on complete blood count, history of coagulopathies, hyperkalemia, pregnancy, lactation
- •12. Patients with history of peptic ulceration and upper GI hemorrhage
- •13. Patients with uncontrolled hypertension, congestive heart failure
- •14. Patients with prior diagnosed malignant tumours
- •15. Patients having allergy or sensitivity to study drugs and excipients in the formulation.
- •16. .Participating in a clinical research trial within 30 days prior to screening.
- •17. Any other health or mental condition that in the Investigatorâ??s opinion may adversely affect the patientâ??s ability to complete the study or its measures or that may pose significant risk to the patient.
- •18. Female patients who are pregnant, breast feeding, nursing or planning to become pregnant during study participation or did not agree to use an acceptable form of birth control throughout the study.
研究者
相似试验
尚未招募
3 期
A study to assess the safety and effectiveness of the medicine called Nitisinone 2 and 5 mg once daily among patients who have the rare genetic disease named Alkaptonuria.CTRI/2024/03/063760INDIAN COUNCIL OF MEDICAL RESEARCH
已完成
3 期
A clinical trial to study the effect of CPL-2009-0031 in the treatment of patients with uncontrolled Type 2 Diabetes Mellitus.CTRI/2019/04/018763Cadila Pharmaceuticals Limited355
已完成
2 期
Clinical study to compare efficacy and safety of oral CPL-2009-0031 against innovator Sitagliptin in Type-2 Diabetes patients.CTRI/2017/12/010986Cadila Pharmaceutical Limited60
尚未招募
2 期
To study the safety and efficacy of Vitamin D3, Vitamin K2-7 & magnesium , in prevention of COVID 19 infection in health care professional (HCP)CTRI/2020/06/026191Suraksha Pharma Private Limited
终止
不适用
Double-blind, Double-dummy, Randomised, Parallel-Arm Equivalence [Non-Inferiority] Study Comparing Hydromorphone Hydrochloride Extended-Release [HHER] Capsules to MS Contin Tablets, Dosed at a Ratio of 1:7.5 to relieve pain, in Cancer or Non-Cancer Patients with a History of Moderate to Severe PaiACTRN12605000696695Mundipharma Pty Limited168